Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study-Reference-Cited by-同舟云学术

Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study

Published:2017-12 Issue:6 Volume:50 Page:789-797
ISSN:1684-1182
Container-title:Journal of Microbiology, Immunology and Infection
language:en
Short-container-title:Journal of Microbiology, Immunology and Infection

Author:

Tsai Mao-Song,Chang Sui-Yuan,Lin Shu-Wen,Kuo Ching-Hua,Sun Hsin-Yun,Wu Bin-Ru,Tang Sue-Yo,Liu Wen-Chun,Su Yi-Ching,Hung Chien-Ching,Chang Shan-Chwen

Funder

Taiwan Centers for Disease Control

National Taiwan University Hospital

Kirby Institute

University of New South Wales

Centers for Disease Control

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy

Reference38 articles.

1. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel;Gunthard;JAMA,2014

2. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults;Hoen;J Int AIDS Soc,2014

3. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012;Williams;HIV Med,2012

4. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS;Arathoon;Int J STD AIDS,2013

5. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study;Molina;Lancet,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients;International Journal of Antimicrobial Agents;2019-07

2. Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis;Bioscience Reports;2019-05

3. Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice;Journal of Pharmacology and Experimental Therapeutics;2018-02-23